ADMA

The Week

Jasper Therapeutics (JSPR) gained 6.27% this week to close at $0.51, while the S&P 500 slipped 0.47%. The stock outperformed the benchmark by roughly 6.74 percentage points. The week was bumpy rather than one-way: Monday (19 Oct) dipped to $0.46, the week’s low, before Tuesday (20 Oct) jumped to $0.5285 on heavier volume; Wednesday (21 Oct) touched the week’s high of $0.5399, then Thursday (22 Oct) consolidated on lighter turnover, and Friday (23 Oct) pushed back to close at $0.51. Weekly amplitude was around 17%, with the bulk of volume coming in the first three sessions.

Key Events

Company filings this week included a DEF 14A proxy statement and an amended SC TO-I/A tender offer filing, neither of which carried product or financial updates. On the news front, Wednesday (21 Oct) brought a sector note on biotech clinical inflection points and revenue divergence; after Friday’s close into Saturday (24 Oct), a headline showed Jasper Therapeutics climbing nearly 9%, in line with the stock’s late-week push. Overall, the company itself had no new pipeline or earnings disclosure this week, so the move appeared tied to sector sentiment and short-term flows.

Analyst Ratings

Two analysts cover the stock and both rate it a buy, giving a consensus rating of strong buy. The consensus target price is $20, roughly 3821.6% above the latest close, with the target range anchored at a single level of $20, suggesting little disagreement among brokers. Within the biotech industry, the stock ranks 398th out of 511 names, placing it in the lower half. These are broker views and do not constitute a recommendation from this report.

The Week Ahead

Next week’s macro calendar is heaviest on Tuesday (27 Oct): durable goods orders, durable goods ex-transport, FHFA house prices, Case Shiller home price indices, new home sales, and consumer confidence are all due. Monday (26 Oct) brings the Dallas Fed manufacturing activity index. On the company side, there is no confirmed earnings date, so attention shifts to any follow-up from this week’s tender offer filing.

In Short

JSPR rose 6.27% this week on a relatively quiet company news flow, with the gain largely tied to sector sentiment and short-term positioning. Brokers see a strong buy with a target far above spot, while valuations show a P/B near 10.1x and negative trailing EPS, and the stock sits in the lower half of its industry ranking. The next checkpoints are macro data’s influence on biotech risk appetite and whether the tender offer filing brings fresh company-level news.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.